The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
An imidazopyridine that is 1H--imidazo[4,5-b]pyridine which is substituted at positions 1, 2, and 6 by methyl, amino, and phenyl groups, respectively. It is the most abundant of the mutagenic heterocyclic amines found in cooked meat and fish.
ABCB1A protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [ABCB1A protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
ABCB1B protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [ABCB1B protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
ABCC2 protein results in increased transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ABCC2 mRNA [Cyclosporine results in decreased activity of ABCC2 protein] which affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine ABCC2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [ABCC2 protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
ABCC3 protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [ABCC3 protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of ABCG2 protein ABCG2 gene polymorphism results in decreased transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; ABCG2 protein results in decreased transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ABCG2 mRNA ABCG2 protein results in increased transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine ABCG2 protein results in increased secretion of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [ABCG2 protein results in increased export of bisbenzimide ethoxide trihydrochloride]; [3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester results in decreased activity of ABCG2 protein] which results in increased transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; Beclomethasone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]; Cadmium Chloride inhibits the reaction [ABCG2 protein results in increased transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]; Dexamethasone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]; Estradiol inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]; Methylprednisolone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]; Triamcinolone inhibits the reaction [ABCG2 protein affects the transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] ABCG2 protein affects the abundance of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine ABCG2 results in increased transport of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine ABCG2 affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine ABCG2 protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [ABCG2 protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ACTA2 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of ACTA2 mRNA
[3'-methoxy-4'-nitroflavone results in decreased activity of AHR protein] which results in decreased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; AHR mutant form inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A1 mRNA]; AHR mutant form inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 mRNA] AHR protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine binds to ALB protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of ALB mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ALB mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased methylation of ANGPTL4 promoter] which results in decreased expression of ANGPTL4 mRNA; [decitabine co-treated with trichostatin A] inhibits the reaction [[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased methylation of ANGPTL4 promoter] which results in decreased expression of ANGPTL4 mRNA]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of APC gene APC protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased mutagenesis of APC gene 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of APC; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of APC gene
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of APP protein; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of APP protein modified form
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of BAX mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of BAX protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in decreased expression of BAX protein Hexachlorocyclohexane promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of BAX protein]
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased expression of BCL2 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of BCL2 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of BCL2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of BTN1A1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of BTN1A1 mRNA
[2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased activity of CASP3 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased activity of CASP3 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of CASP3 protein modified form
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased activity of CAT protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Buprenorphine] results in increased activity of CAT protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CAT mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CCNA2 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CCNA2 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CCNA2 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CCND1 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CCND1 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CCND1 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of CCND1 mRNA; Plant Preparations inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CCND1 mRNA] PhIP increases expression of Ccnd1 mRNA and protein in rat mammary gland
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CCNH mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CCNH protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CDK1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CDK1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CDK4 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CDK4 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CDKN1A mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CDKN1A protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CDKN2A mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CDKN2A protein
CEBPB protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of CEBPB protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CKM mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CKM mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased methylation of CORO1A promoter [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased methylation of CORO1A promoter] which results in decreased expression of CORO1A mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] affects the expression of CSN2 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CSN2 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CSN2 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CSN3 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CSN3 mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CTNNB1 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of CTNNB1 gene 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CTNNB1 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CTNNB1 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] affects the localization of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of CTNNB1 mRNA; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased mutagenesis of CTNNB1 gene; Plant Preparations inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CTNNB1 mRNA]
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in decreased expression of CTSD mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CTSD protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased activity of CYP1A1 protein; CYP1A1 results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased expression of CYP1A1 mRNA; [[CYP1A2 protein co-treated with CYP1A1 protein] results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [Benzo(a)pyrene co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased expression of CYP1A1 mRNA; [CYP1A1 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine; [CYP1A1 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [CYP1A2 protein co-treated with CYP1A1 protein] results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; AHR mutant form inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A1 mRNA]; alpha-naphthoflavone inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A1 mRNA]; xanthohumol promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A1 mRNA] [CYP1A1 protein results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine; [CYP1A1 protein results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A1 protein CYP1A1 protein results in increased metabolism of and results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; lead nitrate inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A1 protein] CYP1A1 gene SNP affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CYP1A1 mRNA
CYP1A2 protein results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine CYP1A2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [CYP1A2 protein results in decreased ethylation of Phenacetin]; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1A2 mRNA; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with CYP1A2 protein] results in increased mutagenesis of HPRT1 gene; [[CYP1A2 protein co-treated with CYP1A1 protein] results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [CYP1A2 protein co-treated with CYP1A1 protein] results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [CYP1A2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine; [CYP1A2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [CYP1A2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine metabolite; AHR mutant form inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 mRNA]; alpha-naphthoflavone inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 mRNA]; CYP1A2 protein results in increased hydroxylation of and results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; CYP1A2 protein results in increased hydroxylation of and results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; CYP1A2 protein results in increased metabolism of and results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; CYP1A2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; CYP1A2 protein results in increased oxidation of and results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; furafylline inhibits the reaction [CYP1A2 protein results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] CYP1A2 results in increased oxidation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine CYP1A2 protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine CYP1A2 protein polymorphism results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; CYP1A2 protein results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; CYP1A2 results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [CYP1A2 protein co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased mutagenesis of APRT gene; [CYP1A2 protein results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine; [CYP1A2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; CYP1A2 protein results in increased metabolism of and results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine CYP1A2 protein results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 protein CYP1A2 affects the oxidation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [1-Naphthylisothiocyanate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in decreased expression of CYP1A2 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 1-Naphthylisothiocyanate] results in decreased expression of CYP1A2 protein; Caffeine promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 mRNA]; CYP1A2 protein results in increased metabolism of and results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; lead nitrate inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 mRNA]; lead nitrate inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1A2 protein] CYP1A2 gene SNP affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of CYP1B1 mRNA; [CYP1B1 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine; [CYP1B1 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; Fulvestrant inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1B1 mRNA]; IL6 protein promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1B1 mRNA] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of CYP1B1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased activity of CYP1B1 protein
CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine; [CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
CYP2D6 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine [CYP2D6 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-amino-1-methyl-6-(4-hydroxyphenyl)imidazo(4,5-b)pyridine
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP2E1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine promotes the reaction [Ethanol results in increased expression of CYP2E1 mRNA]; 5,15-diphenylporphyrin inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP2E1 mRNA]; Ethanol promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP2E1 mRNA]; fulvestrant inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP2E1 mRNA]
CYP3A4 protein results in increased metabolism of and results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP3A4 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased activity of DDC protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of DDC mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of DNMT1 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of DNMT1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine binds to and results in increased activity of ESR1 protein; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [Estradiol binds to and results in increased activity of ESR1 protein]; [fulvestrant results in decreased expression of ESR1 protein] which results in decreased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; Estradiol inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine binds to ESR1 protein]; fulvestrant inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased activity of ESR1 protein] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ESR1 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ESR1 protein ESR1 protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ESR2 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ESR2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of FOS mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of FOS protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of GGT1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of GGT1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of GPX2 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of GPX2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of GPX4 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of GPX4 mRNA
GSTA1 gene polymorphism affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of GSTA1 mRNA [xanthohumol co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased expression of GSTA1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of GSTA3 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of GSTA3 mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in decreased expression of GSTP1 mRNA GSTP1 protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of GSTP1 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of GSTP1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of H2AX protein modified form 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of H2AX protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased methylation of H3-4 protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 4-biphenylamine co-treated with Benzo(a)pyrene co-treated with Tetrachlorodibenzodioxin] results in decreased methylation of H3-4 protein
kaempferol inhibits the reaction [HBB gene polymorphism results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]; Quercetin inhibits the reaction [HBB gene polymorphism results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] HBB protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of HBB mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of HBB-B1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of HMGB2 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of HMGB2 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of HMOX1 mRNA [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in decreased expression of HMOX1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of HMOX1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HPRT1 gene; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HPRT1 intron [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with CYP1A2 protein] results in increased mutagenesis of HPRT1 gene; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct] which results in increased mutagenesis of HPRT1 gene; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased abundance of N-(deoxyguanosin-8-yl)-2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased mutagenesis of HPRT1 gene; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HPRT1 intron] which affects the splicing of HPRT1 mRNA Ascorbic Acid inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HPRT1 gene]; beta Carotene inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HPRT1 gene]; Vitamin E inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HPRT1 gene]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of HRAS mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of HRAS protein HRAS protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased abundance of Reactive Oxygen Species]; HRAS protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NOX1 protein]; HRAS protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK1 protein]; HRAS protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK3 protein] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HRAS gene HRAS protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of and results in increased activity of HRAS; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct] which results in increased mutagenesis of HRAS gene; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HRAS gene] which results in increased activity of HRAS protein; Dietary Fats affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of HRAS gene]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of HSD17B10 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of HSD17B10 mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in decreased expression of HSPD1 mRNA; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of HSPD1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of HSPD1 mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of HSPE1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of HSPE1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of ID3 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ID3 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ID4 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of ID4 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of IGFBP2 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of IGFBP2 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of IL1B mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of IL1B mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased secretion of IL2 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 mRNA]; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL2 protein] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of IL2 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of IL6 mRNA [IL6 protein co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in decreased expression of MIR27B mRNA; IL6 protein promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of CYP1B1 mRNA]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of IL6ST mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of IL6ST protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in decreased expression of BAX protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased activity of STAT5A protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased expression of BCL2 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased expression of STAT5A protein modified form
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of JUN mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of JUN protein [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of JUN mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of and affects the localization of KDM1A protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with 4-biphenylamine co-treated with Benzo(a)pyrene] affects the localization of KDM1A protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of MAOB mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MAOB mRNA
fulvestrant inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MAPK1 protein modified form]; HRAS protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK1 protein] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [lipoteichoic acid results in increased phosphorylation of MAPK1 protein]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK3 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MAPK3 protein modified form fulvestrant inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MAPK3 protein modified form]; HRAS protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of MAPK3 protein] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [lipoteichoic acid results in increased phosphorylation of MAPK3 protein]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MCM7 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MCM7 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of MKI67 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MKI67 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased secretion of MMP9 protein U 0126 inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MMP9 protein]
MSH6 protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MSH6 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MT1 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MT1A mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MT2A mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of MT2A mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MYC protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MYC protein alternative form [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of MYC mRNA; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of MYC protein; [Dietary Fats co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased expression of MYC mRNA; Caffeine promotes the reaction [[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of MYC mRNA]; Plant Preparations promotes the reaction [[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of MYC mRNA] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of MYC mRNA
NAT1 protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NAT1 mRNA
NAT2 protein polymorphism results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; NAT2 protein results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of NAT2 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NAT2 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine affects the activity of NAT2 polymorphism [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine affects the activity of NAT2 polymorphism] which affects the chemical synthesis of Glucose
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NFE2L2 mRNA [2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased expression of NFE2L2 mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of NOS2 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NOS2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NOX1 protein [diphenyleneiodonium results in decreased activity of NOX1 protein] inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased abundance of Reactive Oxygen Species]; [diphenyleneiodonium results in decreased activity of NOX1 protein] which results in decreased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; HRAS protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NOX1 protein]; NOX1 protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased abundance of Reactive Oxygen Species]; U 0126 inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NOX1 protein] NOX1 protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PDGFA mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PDGFA protein PhIP increases expression of Pdgfa mRNA and protein in rat mammary gland
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PGR protein alternative form 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PGR mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PGR protein fulvestrant inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PGR protein alternative form]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PHB1 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PHB1 protein PhIP increases expression of Phb1 mRNA and protein in rat mammary gland
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PIK3R1 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PIK3R1 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PLK2 mRNA PhIP increases expression of Plk2 mRNA and protein in rat mammary gland
[CYP1A2 protein co-treated with POR protein co-treated with OAT protein] results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in decreased expression of BAX protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased activity of STAT5A protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased expression of BCL2 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased expression of STAT5A protein modified form 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased secretion of PRL protein]; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of and results in increased secretion of PRL protein; Fulvestrant inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of and results in increased secretion of PRL protein]
PTGS2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PTGS2 protein fulvestrant inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of PTGS2 protein] [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of RALB mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of RALB mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of RASA1 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of RASA1 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of RASGRF2 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of RASGRF2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased phosphorylation of RB1 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of RB1 protein modified form
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of RBP1 mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of RBP1 protein PhIP increases expression of Rbp1 mRNA and protein in rat mammary gland
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of RPL36 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of RPL36 mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in decreased expression of RPS6 mRNA; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of RPS6 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of RPS6 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of SCD mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of SCD1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of SCD1 mRNA [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] results in increased expression of SCD mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [SLC22A2 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased activity of SLC22A2 protein
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased activity of SLC22A3 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [SLC22A3 protein results in increased import of 4-(4-(dimethylamino)styryl)-1-methylpyridinium iodide]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased activity of SLC22A6 protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [SLC22A6 protein results in increased import of 6-carboxyfluorescein]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [SLC22A8 protein results in increased import of 6-carboxyfluorescein]; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine promotes the reaction [2-amino-9H-pyrido(2,3-b)indole inhibits the reaction [SLC22A8 protein results in increased import of 6-carboxyfluorescein]]; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine promotes the reaction [2-amino-9H-pyrido(2,3-b)indole results in decreased activity of SLC22A8 protein]; 2-amino-9H-pyrido(2,3-b)indole promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [SLC22A8 protein results in increased import of 6-carboxyfluorescein]]; 2-amino-9H-pyrido(2,3-b)indole promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased activity of SLC22A8 protein]
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased activity of STAT5A protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with [Dexamethasone co-treated with INS protein co-treated with PRL protein]] results in increased expression of STAT5A protein modified form 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of STAT5A mRNA; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of STAT5A protein PhIP increases expression of Stat5a mRNA and protein in rat mammary gland
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of SULT1A1 mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [SULT1A1 protein results in increased sulfation of Estradiol]; [2,6-dichloro-4-nitrophenol results in decreased activity of SULT1A1 protein] which results in decreased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [SULT1A1 protein co-treated with SULT1A2 protein] results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [SULT1A1 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct; SULT1A1 protein results in increased metabolism of and results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; SULT1A1 protein results in increased metabolism of and results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine SULT1A1 protein results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine SULT1A1 protein results in increased susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of SULT1A1 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of TAGLN mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TAGLN mRNA
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dietary Fats] affects the expression of TF mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TF mRNA
[Benzo(a)pyrene co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] results in increased mutagenesis of TK1 gene 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased mutagenesis of TK1 gene
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased methylation of TMEM37 promoter [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased methylation of TMEM37 promoter] which results in decreased expression of TMEM37 mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [lipoteichoic acid results in increased expression of and results in increased secretion of TNF protein]; 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [lipoteichoic acid results in increased expression of TNF mRNA]; Dactinomycin promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [lipoteichoic acid results in increased expression of TNF mRNA]]; Tetradecanoylphorbol Acetate inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [lipoteichoic acid results in increased expression of and results in increased secretion of TNF protein]] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TNF protein 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased stability of TNF mRNA U 0126 inhibits the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TNF protein]
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of TOP2A mRNA 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TOP2A mRNA
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of TP53 protein myricetin affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine affects the expression of TP53 mRNA] 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased phosphorylation of TP53 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased methylation of TP53I3 promoter] which results in decreased expression of TP53I3 mRNA
UGT1A1 protein results in increased glucuronidation of and results in decreased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; xanthohumol promotes the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of UGT1A1 mRNA]
XPA protein affects the reaction [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct] XPA protein affects the susceptibility to 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[ABCB1A protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[ABCB1B protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[ABCC2 protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[ABCC3 protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
ABCG2 protein affects the transport of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine [ABCG2 protein affects the metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[CYP1A1 protein results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine [[CYP1A2 protein co-treated with CYP1A1 protein] results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [CYP1A1 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[[CYP1A2 protein co-treated with CYP1A1 protein] results in increased hydroxylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [CYP1A2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine; [CYP1A2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine metabolite [CYP1A2 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[CYP1B1 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
[CYP2C19 protein results in increased metabolism of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased chemical synthesis of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine inhibits the reaction [Estradiol results in increased activity of ESR1 protein] 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased activity of ESR1 protein
[GSTP1 protein co-treated with Glutathione] inhibits the reaction [[Adenosine Triphosphate results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct]; [GSTP1 protein co-treated with Glutathione] inhibits the reaction [Adenosine Triphosphate results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of GSTP1 protein GSTP1 protein results in decreased susceptibility to 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
NAT1 protein affects the acetylation of and affects the activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine NAT1 protein results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
4-biphenylamine inhibits the reaction [NAT2 protein results in increased acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] NAT2 protein results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine affects the expression of PDIA3 protein [2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dihydrotestosterone] affects the expression of PDIA3 protein
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine affects the expression of RAB7A protein [2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dihydrotestosterone] affects the expression of RAB7A protein
[2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dihydrotestosterone] affects the expression of RPS7 protein 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine affects the expression of RPS7 protein
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine affects the expression of SAR1A protein [2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dihydrotestosterone] affects the expression of SAR1A protein
SULT1A1 protein results in increased metabolism of and results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine SULT1A1 protein results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
UGT1A1 promoter polymorphism affects the reaction [2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine binds to Glucuronides]; UGT1A1 protein promotes the reaction [2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine binds to Glucuronides]; UGT1A1 protein results in increased glucuronidation of and results in decreased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine UGT1A1 promoter polymorphism affects the metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine UGT1A1 protein results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine UGT1A1 protein results in increased glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
UGT1A4 protein results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine UGT1A4 protein promotes the reaction [2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine binds to Glucuronides] UGT1A4 protein results in increased glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
UGT1A9 protein promotes the reaction [2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine binds to Glucuronides] UGT1A9 protein results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine UGT1A9 protein results in increased glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine
browse the term
